Device Trial Radar · NCT04702802
Study to Evaluate the Safety of the Viscoelastic Substance PRO-149, Compared to Healon® EndoCoat.
Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Sep 7, 2021
Primary completion
Oct 29, 2021
Study completion Oct 29, 2021
Sponsor
- Lead sponsor
- Laboratorios Sophia S.A de C.V.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 11, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pilot, controlled, parallel group, open, randomized clinical trial to evaluate the safety of the viscoelastic substance PRO-149 (sodium hyaluronate 3%) after trans-surgical administration as a device in performing phacoemulsification and intraocular lens implantation in 36 patients with age-related cataract, compared to Healon® EndoCoat (sodium hyaluronate 3%).
Conditions
- Age-related Cataract
- Phacoemulsification
Interventions
Sodium hyaluronate 3%Device
During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
Sodium hyaluronate 3%Device
During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Corneal Endothelial Cell CountTime frame: Days: -15 (±2) (eligibility visit), and 29 (±2) (final visit)
- Change in Intraocular Pressure (IOP)Time frame: Days: -15 (±2) (eligibility visit [EV]), 1 (first safety evaluation visit [V1]), 8 (±2) (second safety evaluation visit [V2]), and 29 (±2) (final visit [FV])
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SalaUno Salud, S.A.P.I. de C.V.
Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.